CHL Medical Partners

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of the Rapid IntraVascular Start (RIVS) catheter, an FDA-cleared device designed to facilitate rapid, safe, and effective peripheral intravenous (IV) insertion. By focusing on this innovative technology, Vascular Pathways aims to improve patient care and streamline the IV insertion process in clinical settings.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

CareWell Urgent Care is a healthcare provider operating emergency care centers throughout the New England region, with its headquarters located in Tewksbury, Massachusetts. The organization focuses on delivering accessible and efficient urgent care services, catering to a variety of common illnesses and injuries, including cold infections, fractures, rashes, and chronic conditions. CareWell Urgent Care features on-site laboratories, x-ray capabilities, and the ability to dispense common medications, allowing patients to receive timely treatment without the need for an appointment. This patient-centered approach is designed to meet the urgent healthcare needs of the community effectively.

Ambra Health is a medical data and image management company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation by offering secure and easy access to medical images, facilitating internal adoption, and strengthening collaboration among healthcare organizations. With its intuitive and flexible design, Ambra's solutions enable health systems, radiology practices, and clinical research organizations to improve workflows related to imaging and patient care. The company's technology aims to make medical images and data accessible from anywhere, significantly enhancing operational efficiency and business outcomes within the healthcare sector.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Ambra Health is a medical data and image management company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation by offering secure and easy access to medical images, facilitating internal adoption, and strengthening collaboration among healthcare organizations. With its intuitive and flexible design, Ambra's solutions enable health systems, radiology practices, and clinical research organizations to improve workflows related to imaging and patient care. The company's technology aims to make medical images and data accessible from anywhere, significantly enhancing operational efficiency and business outcomes within the healthcare sector.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of the Rapid IntraVascular Start (RIVS) catheter, an FDA-cleared device designed to facilitate rapid, safe, and effective peripheral intravenous (IV) insertion. By focusing on this innovative technology, Vascular Pathways aims to improve patient care and streamline the IV insertion process in clinical settings.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis, a common spinal condition. Founded in 2005 and headquartered in Aliso Viejo, California, the company develops and markets its mild device, which provides an outpatient treatment option that is fluoroscopically guided and does not require implants. This device encompasses a range of instruments including tissue sculptors, surgical clamps, and bone sculpters, allowing physicians to effectively relieve pressure on the spinal nerves and restore mobility with local anesthesia. Vertos Medical’s innovative approach offers patients a less invasive option compared to traditional lumbar decompression surgeries, making significant advancements in spinal healthcare.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis, a common spinal condition. Founded in 2005 and headquartered in Aliso Viejo, California, the company develops and markets its mild device, which provides an outpatient treatment option that is fluoroscopically guided and does not require implants. This device encompasses a range of instruments including tissue sculptors, surgical clamps, and bone sculpters, allowing physicians to effectively relieve pressure on the spinal nerves and restore mobility with local anesthesia. Vertos Medical’s innovative approach offers patients a less invasive option compared to traditional lumbar decompression surgeries, making significant advancements in spinal healthcare.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in the development of novel therapeutics aimed at treating degenerative diseases, particularly retinal disorders. It focuses on creating small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins in the retina, which are implicated in serious conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam Pharmaceuticals has developed an orally active pharmacological chaperone that effectively binds to misfolded rod opsin, a protein associated with retinitis pigmentosa, and facilitates its proper trafficking to the surface of rod cells, thereby aiming to mitigate the effects of this rare and incurable genetic disease that leads to blindness.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry, headquartered in Chicago, Illinois. The company offers a comprehensive approach to pharmacy services by integrating just-in-time dispensing with electronic prescription ordering, medication administration, and formulary management. This innovative model enables nursing and assisted living communities to enhance patient care while simultaneously reducing costs and improving operational efficiency. Millennium prioritizes medication accuracy and delivery timeliness, ensuring compliance with regulatory requirements and supporting healthcare providers in meeting their patient care objectives.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Ascend Health Corporation is a healthcare provider specialising in behavioural health. It operates inpatient and day hospital facilities offering personalised care for children, adolescents, adults, and seniors. Ascend focuses on integrating its services with local community healthcare systems to deliver high-quality mental health and chemical dependency treatments.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments by modifying and repurposing existing drugs. Headquartered in Weston, Florida, the company is advancing two primary development programs that utilize established therapies to create safer and more effective treatments for various types of cancer, including metastatic breast cancer, pancreatic cancer, and glioblastoma. Among its notable offerings are ODSH, a low anticoagulant heparin derivative designed to mitigate chemotherapy-induced reductions in platelet counts, and Disulfiram-Copper Chelate, which employs distinct mechanisms targeting cancer stem cells to combat tumor progression. Founded in 2002, Cantex Pharmaceuticals aims to address significant unmet medical needs in oncology, positioning itself within high-value market opportunities.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry, headquartered in Chicago, Illinois. The company offers a comprehensive approach to pharmacy services by integrating just-in-time dispensing with electronic prescription ordering, medication administration, and formulary management. This innovative model enables nursing and assisted living communities to enhance patient care while simultaneously reducing costs and improving operational efficiency. Millennium prioritizes medication accuracy and delivery timeliness, ensuring compliance with regulatory requirements and supporting healthcare providers in meeting their patient care objectives.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

GeneOhm Sciences is a biotechnology company that specializes in the design, development, and delivery of nucleic acid-based diagnostic solutions aimed at addressing unmet diagnostic needs in various diseases, including inherited diseases, infectious diseases, and oncology. Established in 2001 in San Diego, California, and later merging with Infectio Diagnostic, Inc. in 2004, the company leverages a robust portfolio of proprietary technology and industry expertise to create rapid diagnostic systems. These systems are capable of detecting and identifying infectious agents and genetic variations, with a focus on providing FDA-approved molecular tests that deliver results in under two hours. GeneOhm's notable products include the MRSA Assay for detecting methicillin-resistant Staphylococcus aureus and the StrepB Assay for identifying Group B Streptococcus in pregnant women. The company was recently acquired by the BD Pharmaceuticals group, further enhancing its capabilities in the diagnostic field.

GeneOhm Sciences is a biotechnology company that specializes in the design, development, and delivery of nucleic acid-based diagnostic solutions aimed at addressing unmet diagnostic needs in various diseases, including inherited diseases, infectious diseases, and oncology. Established in 2001 in San Diego, California, and later merging with Infectio Diagnostic, Inc. in 2004, the company leverages a robust portfolio of proprietary technology and industry expertise to create rapid diagnostic systems. These systems are capable of detecting and identifying infectious agents and genetic variations, with a focus on providing FDA-approved molecular tests that deliver results in under two hours. GeneOhm's notable products include the MRSA Assay for detecting methicillin-resistant Staphylococcus aureus and the StrepB Assay for identifying Group B Streptococcus in pregnant women. The company was recently acquired by the BD Pharmaceuticals group, further enhancing its capabilities in the diagnostic field.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Eunoe, Inc. is a San Francisco Bay-area medical device company focused on the treatment of neurological disorders through the management of cerebrospinal fluid.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

RxCentric is an e-health business-to-business company that facilitates connections between physicians and essential drug information and educational resources. By offering online marketing solutions tailored for pharmaceutical companies, RxCentric enables healthcare professionals to access comprehensive drug information quickly and efficiently. The company utilizes trusted authoritative sources to ensure that physicians receive accurate and reliable data, thereby enhancing their decision-making capabilities in clinical settings.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

RxCentric is an e-health business-to-business company that facilitates connections between physicians and essential drug information and educational resources. By offering online marketing solutions tailored for pharmaceutical companies, RxCentric enables healthcare professionals to access comprehensive drug information quickly and efficiently. The company utilizes trusted authoritative sources to ensure that physicians receive accurate and reliable data, thereby enhancing their decision-making capabilities in clinical settings.

Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

Molecular Staging Inc., a life sciences tool company, specializes in developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings include protein microarrays for proteomics research, whole-genome amplification tools to overcome limited DNA sample constraints, and multiplexed diagnostics for enhanced disease detection. These products cater to applications in genomics, pharmacogenomics, and diagnostics.

Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

RxCentric is an e-health business-to-business company that facilitates connections between physicians and essential drug information and educational resources. By offering online marketing solutions tailored for pharmaceutical companies, RxCentric enables healthcare professionals to access comprehensive drug information quickly and efficiently. The company utilizes trusted authoritative sources to ensure that physicians receive accurate and reliable data, thereby enhancing their decision-making capabilities in clinical settings.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.